Hofseth BioCare ("HBC") announces the grant of its European Patent Application No. 08861633.9 for Compositions and Methods for Increasing Iron Absorption. This intellectual property grant gives HBC the sole marketing claim rights to for increasing iron uptake in humans from marine protein sources across the European Union.

Situational anemia (iron deficiency) in humans is the single most devastating nutritional problem globally and reduced iron uptake is the primary cause of this condition. Anemia is affecting about a quarter of the people globally. Iron-deficiency anemia affects nearly 1 billion, and in 2013, anemia due to iron deficiency resulted in about 183,000 deaths. It is more common in females than males, among children, during pregnancy, and in the elderly population.

HBC has published several papers showing how supplementation with HBC's Salmon Protein Hydrolysate, ProGo®, increases both iron uptake and circulating hemoglobin levels in anemic humans and this European grant will help HBC maintain its globally exclusive position of this significant nutritional claim for any marine protein hydrolysate.

For further information, please contact:

Tor Erik Andersen, CEO of Hofseth BioCare ASA
Mob: +47 911 79 854
E-mail: tea@hofsethbiocare.no

Dr. Bomi Framroze, CSO of Hofseth BioCare ASA
Tel: +91 982006524
Email: bf@hofsethbiocare.no

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

 
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hofseth Biocare ASA via Globenewswire